Skip to content

Search

Specificity of the Modified Jones Criteria

Jonathan Carapetis AM AM MBBS FRACP FAFPHM PhD FAHMS Executive Director; Co-Head, Strep A Translation; Co-Founder of REACH 08 6319 1000 contact@

Subcutaneous infusion of high-dose benzathine penicillin G is safe, tolerable, and suitable for less-frequent dosing for rheumatic heart disease secondary prophylaxis: a phase 1 open-label population pharmacokinetic study

Since 1955, the recommended strategy for rheumatic heart disease secondary prophylaxis has been benzathine penicillin G injections administered intramuscularly every 4 weeks. Due to dosing frequency, pain, and programmatic challenges, adherence is suboptimal. It has previously been demonstrated that BPG delivered subcutaneously at a standard dose is safe and tolerable and has favorable pharmacokinetics, setting the scene for improved regimens with less frequent administration.

Expert researchers converge on Broome to tackle health challenges in Northern Australia

Over 100 researchers and health professionals from around Australia have united in Broome this week to address the major health battles facing people living in the tropical north of the country.

Bold bid to end rheumatic heart disease

Some of the nation’s leading medical researchers will converge on Darwin this week to step out a plan to wipe out rheumatic heart disease.

Call for Group A streptococcal infections to become notifiable diseases

Researchers at The Kids Research Institute Australia say Group A Streptococcus should become a nationally notifiable disease in Australia.

Trans-Tasman partnership to tackle rheumatic heart disease

Researchers at The Kids Research Institute Australia have begun a comprehensive research project into vaccines aimed at tackling rheumatic fever.

Clinical development strategy for a candidate group A streptococcal vaccine

This review outlines a clinical development strategy detailing the phases of development required for registration of a candidate Group A streptococci vaccin

Rheumatic Heart Disease Severity, Progression and Outcomes: A Multi‐State Model

The prognosis of young Indigenous Australians diagnosed with severe RHD is bleak; interventions must focus on earlier detection and treatment

Rheumatic heart disease across the Western Pacific: not just a Pacific Island problem

We aimed to review RHD burden in Western Pacific Region outside Oceania to identify countries with high RHD burden